


WHAT IS CLAIMED IS:

1. A method for treating a cancer in a human subject in need thereof, comprising administering to the human subject an effective amount of an inhibitor of human CD73 and an inhibitor of A2A adenosine receptor and/or A2B adenosine receptor, wherein:
 - (1) the inhibitor of human CD73 comprises:
 - (a) an antibody comprising a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);
the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
and
comprising a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6);
 - (b) an antibody that binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;
 - (c) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25; or
 - (d) an antibody comprising a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
an antibody comprising a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);

- (e) an antibody that binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70;
- (f) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31;
- (g) an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31;
- (h) an antibody selected from the group consisting of 11E1, Medi9447, CPI-006, and BMS-986179; or
- (i) an inhibitor selected from the group consisting of CB-708 and AB680; and
- (2) the inhibitor of A2A adenosine receptor and/or A2B adenosine receptor (A2A/A2B) comprises a compound of:

(a) Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy² is 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl of Cy² are each optionally substituted with 1, 2, or 3 groups each independently selected from C₁₋₃ alkyl, C₁₋₃ alkoxy, NH₂, NH(C₁₋₃ alkyl) and N(C₁₋₃ alkyl)₂;


R² is selected from phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-7 membered heteroaryl)-C₁₋₃ alkyl-, (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl-, and OR^{a2}, wherein the phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-7 membered heteroaryl)-C₁₋₃ alkyl-, and (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl- of R² are each optionally substituted with 1, 2, or 3 independently selected R^C substituents;

R^{a2} is (5-7 membered heteroaryl)-C₁₋₃ alkyl- optionally substituted with 1 or 2 independently selected R^C substituents;

each R^C is independently selected from halo, C_{1-6} alkyl, C_6 aryl, 5-7 membered heteroaryl, (4-7 membered heterocycloalkyl)- C_{1-3} alkyl-, OR^{a4} , and $NR^{c4}R^{d4}$; and

each R^{a4} , R^{c4} , and R^{d4} are independently selected from H and C_{1-6} alkyl;

(b) Formula (II):



or a pharmaceutically acceptable salt thereof, wherein

R^2 is selected from H and CN;

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

L is C_{1-3} alkylene, wherein said alkylene is optionally substituted with 1, 2, or 3 independently selected R^{8D} substituents;

Cy^4 is selected from phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl, wherein the phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{8D} and R^8 ;

each R^8 is independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl- C_{1-3} alkyl, C_{3-7} cycloalkyl- C_{1-3} alkyl, (5-6 membered heteroaryl)- C_{1-3} alkyl, and (4-7 membered heterocycloalkyl)- C_{1-3} alkyl, wherein the C_{1-6} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, C_{3-7} cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl- C_{1-3} alkyl, C_{3-7} cycloalkyl- C_{1-3} alkyl, (5-6 membered heteroaryl)- C_{1-3} alkyl, and (4-7 membered heterocycloalkyl)- C_{1-3} alkyl of R^8 are each optionally substituted with 1, 2, or 3 independently selected R^{8A} substituents;


each R^{8A} is independently selected from halo, C_{1-6} alkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR^{a81} , and $NR^{c81}R^{d81}$, wherein the C_{1-3} alkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{8A} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{a81} , R^{c81} , and R^{d81} is independently selected from H, C_{1-6} alkyl, and 4-7 membered heterocycloalkyl, wherein the C_{1-6} alkyl and 4-7 membered heterocycloalkyl of R^{a81} , R^{c81} , and R^{d81} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{8B} is independently selected from halo and C_{1-3} alkyl; and

each R^{8D} is independently selected from OH, CN, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

(c) Formula (III):



or a pharmaceutically acceptable salt thereof, wherein

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

R^2 is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R^2 are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents;


each R^{2A} is independently selected from D, halo, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^4 is selected from phenyl- C_{1-3} alkyl-, C_{3-7} cycloalkyl- C_{1-3} alkyl-, (5-6 membered heteroaryl)- C_{1-3} alkyl-, and (4-7 membered heterocycloalkyl)- C_{1-3} alkyl wherein the phenyl- C_{1-3} alkyl-, C_{3-7} cycloalkyl- C_{1-3} alkyl-, (5-6 membered heteroaryl)- C_{1-3} alkyl-, and (4-7 membered heterocycloalkyl)- C_{1-3} alkyl- of R^4 are each optionally substituted with 1, 2, or 3 independently selected R^{4A} substituents;

each R^{4A} is independently selected from halo, C_{1-6} alkyl, C_{1-6} haloalkyl, CN, OR^{a41} , and $NR^{c41}R^{d41}$; and

each R^{a41} , R^{c41} , and R^{d41} is independently selected from H and C_{1-6} alkyl; or

(d) Formula (IV):




or a pharmaceutically acceptable salt thereof, wherein

Cy^1 is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy² is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Cy² are each optionally substituted with 1, 2, or 3 independently selected R⁶ substituents;
 each R⁶ is independently selected from halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;
 R² is phenyl-C₁₋₃ alkyl- or (5-6 membered heteroaryl)-C₁₋₃ alkyl-, wherein the phenyl-C₁₋₃ alkyl- and (5-6 membered heteroaryl)-C₁₋₃ alkyl- of R² are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents; and
 each R^{2A} is independently selected from halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl.
 or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy² is 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl of Cy² are each optionally substituted with 1, 2, or 3 groups each independently selected from C₁₋₃ alkyl, C₁₋₃ alkoxy, NH₂, NH(C₁₋₃ alkyl) and N(C₁₋₃ alkyl)₂;

R² is selected from phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-7 membered heteroaryl)-C₁₋₃ alkyl-, (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl-, and OR^{a2}, wherein the phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-7 membered heteroaryl)-C₁₋₃ alkyl-, and (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl- of R² are each optionally substituted with 1, 2, or 3 independently selected R^C substituents;


R^{a2} is (5-7 membered heteroaryl)-C₁₋₃ alkyl- optionally substituted with 1 or 2 independently selected R^C substituents;

each R^C is independently selected from halo, C₁₋₆ alkyl, C₆ aryl, 5-7 membered heteroaryl, (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl-, OR^{a4}, and NR^{c4}R^{d4}; and

each R^{a4}, R^{c4}, and R^{d4} are independently selected from H and C₁₋₆ alkyl.

3. The method of claim 2, wherein the inhibitor of A2A/A2B is selected from:
 3-(5-Amino-2-(pyridin-2-ylmethyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;
 3-(5-Amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;
 3-(5-Amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;
 3-(5-Amino-2-((3-methylpyridin-2-yl)methoxy)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof; and
 3-(2-((5-(1H-Pyrazol-1-yl)-1H-tetrazol-1-yl)methyl)-5-amino-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

4. The method of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (II):



or a pharmaceutically acceptable salt thereof, wherein

R² is selected from H and CN;

Cy¹ is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

L is C₁₋₃ alkylene, wherein said alkylene is optionally substituted with 1, 2, or 3 independently selected R^{8D} substituents;

Cy⁴ is selected from phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl, wherein the phenyl, cyclohexyl, pyridyl, pyrrolidinonyl, and imidazolyl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{8D} and R⁸;

each R⁸ is independently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, C₃₋₇ cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C₁₋₃ alkyl, C₃₋₇ cycloalkyl-C₁₋₃ alkyl, (5-6 membered heteroaryl)-C₁₋₃ alkyl, and (4-7

membered heterocycloalkyl)-C₁₋₃ alkyl, wherein the C₁₋₆ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, phenyl, C₃₋₇ cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C₁₋₃ alkyl, C₃₋₇ cycloalkyl-C₁₋₃ alkyl, (5-6 membered heteroaryl)-C₁₋₃ alkyl, and (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl of R⁸ are each optionally substituted with 1, 2, or 3 independently selected R^{8A} substituents;

each R^{8A} is independently selected from halo, C₁₋₆ alkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR^{a81}, and NR^{c81}R^{d81}, wherein the C₁₋₃ alkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R^{8A} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{a81}, R^{c81}, and R^{d81} is independently selected from H, C₁₋₆ alkyl, and 4-7 membered heterocycloalkyl, wherein the C₁₋₆ alkyl and 4-7 membered heterocycloalkyl of R^{a81}, R^{c81}, and R^{d81} are each optionally substituted with 1, 2, or 3 independently selected R^{8B} substituents;

each R^{8B} is independently selected from halo and C₁₋₃ alkyl; and

each R^{8D} is independently selected from OH, CN, halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl.

5. The method of claim 4, wherein the inhibitor of A2A/A2B is selected from:

3-(5-Amino-2-(hydroxy(phenyl)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;


3-(5-Amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile, or a pharmaceutically acceptable salt thereof;

5-Amino-7-(3-cyano-2-fluorophenyl)-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidine-8-carbonitrile, or a pharmaceutically acceptable salt thereof;

and

3-(5-Amino-2-((2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)phenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-2-fluorobenzonitrile, or a pharmaceutically acceptable salt thereof.

6. The method of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (III):



or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

R² is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of R² are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents;

each R^{2A} is independently selected from D, halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

R⁴ is selected from phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-6 membered heteroaryl)-C₁₋₃ alkyl-, and (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl wherein the phenyl-C₁₋₃ alkyl-, C₃₋₇ cycloalkyl-C₁₋₃ alkyl-, (5-6 membered heteroaryl)-C₁₋₃ alkyl-, and (4-7 membered heterocycloalkyl)-C₁₋₃ alkyl- of R⁴ are each optionally substituted with 1, 2, or 3 independently selected R^{4A} substituents;

each R^{4A} is independently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, CN, OR^{a41}, and NR^{c41}R^{d41}; and

each R^{a41}, R^{c41}, and R^{d41} is independently selected from H and C₁₋₆ alkyl.

7. The method of claim 6, wherein the inhibitor of A2A/A2B is selected from:

3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile;


3-(8-Amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

3-(8-amino-2-(amino(2,6-difluorophenyl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

and

3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

8. The method of claim 1, wherein the inhibitor of A2A/A2B is a compound of Formula (IV):



or a pharmaceutically acceptable salt thereof, wherein

Cy¹ is phenyl which is substituted by 1 or 2 substituents independently selected from halo and CN;

Cy² is selected from 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl of Cy² are each optionally substituted with 1, 2, or 3 independently selected R⁶ substituents;

each R⁶ is independently selected from halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

R² is phenyl-C₁₋₃ alkyl- or (5-6 membered heteroaryl)-C₁₋₃ alkyl-, wherein the phenyl-C₁₋₃ alkyl- and (5-6 membered heteroaryl)-C₁₋₃ alkyl- of R² are each optionally substituted with 1, 2, or 3 independently selected R^{2A} substituents; and

each R^{2A} is independently selected from halo, C₁₋₆ alkyl, and C₁₋₆ haloalkyl.

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8, wherein the inhibitor of A2A/A2B is selected from:

3-(4-amino-2-(pyridin-2-ylmethyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyrimidin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof;

3-(4-amino-2-((3-fluoropyridin-2-yl)methyl)-7-(pyridin-4-yl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof; and

3-(4-amino-7-(1-methyl-1H-pyrazol-5-yl)-2-(pyridin-2-ylmethyl)-2H-[1,2,3]triazolo[4,5-c]pyridin-6-yl)-2-fluorobenzonitrile, or a pharmaceutically acceptable salt thereof.

10. The method of claim 1, wherein the inhibitor of A2A/A2B is 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein the inhibitor of A2A/A2B is 3-(5-Amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
12. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody comprising:
a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);
the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
and
a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6).
13. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70.
14. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25.
15. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody comprising:
a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

16. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70.

17. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

18. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.

19. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 comprises an antibody selected from the group consisting of 11E1, Medi9447, CPI-006, and BMS-986179.

20. The method of any one of claims 1 to 11, wherein the inhibitor of human CD73 is selected from the group consisting of CB-708 and AB680.

21. The method of claim 12, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23, and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

22. The method of claim 12, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:25,

and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

23. The method of claim 15, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:62 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:61, and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

24. The method of claim 15, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:30 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:31, and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

25. The method of claim 15, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:63 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:61, and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

26. The method of claim 15, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:33 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:31, and wherein the compound comprises 3-(8-Amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile.

27. A method for treating a cancer in a human subject in need thereof, comprising administering to the human subject an effective amount of an antibody that binds to human CD73 and an inhibitor of A2A adenosine receptor and/or A2B adenosine receptor, wherein the antibody:

- (a) comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
and
comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3,
wherein:
the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6);
(b) binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70;
(c) binds to human CD73 and competes for binding to human CD73 with an antibody that has
a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain
comprising the amino acid sequence of SEQ ID NO:25;
(d) comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or
MSYEGSNK (SEQ ID NO:40); and
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL
CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39);
(e) binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID
NO:70;
(f) binds to human CD73 and competes for binding to human CD73 with an antibody that has
a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain
comprising the amino acid sequence of SEQ ID NO:31; or
(g) binds to human CD73 and competes for binding to human CD73 with an antibody that has
a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain
comprising the amino acid sequence of SEQ ID NO:31.

28. The method of claim 27, wherein the antibody comprises a VH domain comprising
VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);

the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2); and
the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5); and
the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6).

29. The method of claim 28, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22.

30. The method of claim 28, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24.

31. The method of claim 28, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23.

32. The method of claim 28, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:25.

33. The method of claim 28, wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:22 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:23.

34. The method of claim 28, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:22 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:23.

35. The method of claim 28, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:24 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:25.

36. The method of claim 27, wherein the antibody binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70.

37. The method of claim 27, wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25.

38. The method of claim 27, wherein the antibody comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40); and

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36); and wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

39. The method of claim 38, wherein:

the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);

the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35);

the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);

the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);

the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and

the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).

40. The method of claim 39, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 62.

41. The method of claim 39, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:30.

42. The method of claim 39, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.
43. The method of claim 39, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.
44. The method of claim 39, wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 62 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 61.
45. The method of claim 39, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 62 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.
46. The method of claim 39, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 30 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.
47. The method of claim 38, wherein:
the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
the VH CDR2 comprises the amino acid sequence MSYEGSNK (SEQ ID NO:40);
the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);
the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38); and
the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).
48. The method of claim 47, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 63.
49. The method of claim 47, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:33.
50. The method of claim 47, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.

51. The method of claim 47, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.
52. The method of claim 47, wherein the VH domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 63 and the VL domain is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 61.
53. The method of claim 47, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO: 63 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO: 61.
54. The method of claim 47, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 33 and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 31.
55. The method of claim 27, wherein the antibody binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70.
56. The method of claim 27, wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.
57. The method of claim 27, wherein the antibody binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.
58. The method of any one of claims 27 to 57, wherein the inhibitor is selected from the group consisting of:
7-(5-methylfuran-2-yl)-3-[[6-[[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine,
3-(5-Amino-2-((5-(pyridin-2-yl)-2H-tetrazol-2-yl)methyl)-8-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)benzonitrile,

3-[2-Amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile,
6-(2-Chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine, 5-Bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine, and
EOS100850.

59. The method of any one of claims 1 to 58, wherein the cancer has a high adenosine signature.

60. The method of any one of claims 1 to 59, wherein the cancer is head and neck cancer, colorectal cancer, lung cancer, melanoma, ovarian, bladder, liver cancer, or renal cell carcinoma.